vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and TFS Financial CORP (TFSL). Click either name above to swap in a different company.

TFS Financial CORP is the larger business by last-quarter revenue ($83.7M vs $57.3M, roughly 1.5× RHYTHM PHARMACEUTICALS, INC.). TFS Financial CORP runs the higher net margin — 26.6% vs -83.0%, a 109.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 11.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 4.2%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

TFS Financial Corporation is a US-based financial holding company primarily operating through its retail banking subsidiary. It offers residential mortgage loans, savings accounts, and other consumer financial products, with its core customer base concentrated in Ohio and Florida, mainly serving individual and family clients.

RYTM vs TFSL — Head-to-Head

Bigger by revenue
TFSL
TFSL
1.5× larger
TFSL
$83.7M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+25.0% gap
RYTM
36.9%
11.9%
TFSL
Higher net margin
TFSL
TFSL
109.6% more per $
TFSL
26.6%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
4.2%
TFSL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RYTM
RYTM
TFSL
TFSL
Revenue
$57.3M
$83.7M
Net Profit
$-47.5M
$22.3M
Gross Margin
91.6%
Operating Margin
-82.2%
34.0%
Net Margin
-83.0%
26.6%
Revenue YoY
36.9%
11.9%
Net Profit YoY
-9.6%
-0.7%
EPS (diluted)
$-0.73
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
TFSL
TFSL
Q4 25
$57.3M
$83.7M
Q3 25
$51.3M
$85.5M
Q2 25
$48.5M
$82.0M
Q1 25
$32.7M
$79.1M
Q4 24
$41.8M
$74.8M
Q3 24
$33.3M
$75.1M
Q2 24
$29.1M
$75.5M
Q1 24
$26.0M
$77.1M
Net Profit
RYTM
RYTM
TFSL
TFSL
Q4 25
$-47.5M
$22.3M
Q3 25
$-52.9M
$26.0M
Q2 25
$-46.6M
$21.5M
Q1 25
$-49.5M
$21.0M
Q4 24
$-43.3M
$22.4M
Q3 24
$-43.6M
$18.2M
Q2 24
$-32.3M
$20.0M
Q1 24
$-141.4M
$20.7M
Gross Margin
RYTM
RYTM
TFSL
TFSL
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
RYTM
RYTM
TFSL
TFSL
Q4 25
-82.2%
34.0%
Q3 25
-102.6%
37.9%
Q2 25
-93.4%
33.3%
Q1 25
-143.7%
33.5%
Q4 24
-98.6%
37.9%
Q3 24
-132.0%
30.7%
Q2 24
-139.2%
33.4%
Q1 24
-538.7%
33.6%
Net Margin
RYTM
RYTM
TFSL
TFSL
Q4 25
-83.0%
26.6%
Q3 25
-103.1%
30.4%
Q2 25
-96.1%
26.2%
Q1 25
-151.4%
26.6%
Q4 24
-103.6%
30.0%
Q3 24
-131.2%
24.2%
Q2 24
-110.9%
26.4%
Q1 24
-544.4%
26.9%
EPS (diluted)
RYTM
RYTM
TFSL
TFSL
Q4 25
$-0.73
$0.08
Q3 25
$-0.82
$0.09
Q2 25
$-0.75
$0.08
Q1 25
$-0.81
$0.07
Q4 24
$-0.71
$0.08
Q3 24
$-0.73
$0.07
Q2 24
$-0.55
$0.07
Q1 24
$-2.35
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
TFSL
TFSL
Cash + ST InvestmentsLiquidity on hand
$388.9M
$456.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$139.1M
$1.9B
Total Assets
$480.2M
$17.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
TFSL
TFSL
Q4 25
$388.9M
$456.7M
Q3 25
$416.1M
$429.4M
Q2 25
$291.0M
$452.6M
Q1 25
$314.5M
$463.6M
Q4 24
$320.6M
$465.9M
Q3 24
$298.4M
$463.7M
Q2 24
$319.1M
$560.4M
Q1 24
$201.2M
$594.3M
Stockholders' Equity
RYTM
RYTM
TFSL
TFSL
Q4 25
$139.1M
$1.9B
Q3 25
$148.8M
$1.9B
Q2 25
$-11.9M
$1.9B
Q1 25
$18.9M
$1.9B
Q4 24
$21.7M
$1.9B
Q3 24
$11.2M
$1.9B
Q2 24
$39.3M
$1.9B
Q1 24
$61.6M
$1.9B
Total Assets
RYTM
RYTM
TFSL
TFSL
Q4 25
$480.2M
$17.5B
Q3 25
$506.9M
$17.5B
Q2 25
$372.7M
$17.4B
Q1 25
$386.7M
$17.1B
Q4 24
$392.3M
$17.1B
Q3 24
$363.6M
$17.1B
Q2 24
$381.8M
$17.0B
Q1 24
$258.7M
$17.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
TFSL
TFSL
Operating Cash FlowLast quarter
$-25.4M
$58.7M
Free Cash FlowOCF − Capex
$57.1M
FCF MarginFCF / Revenue
68.2%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
2.64×
TTM Free Cash FlowTrailing 4 quarters
$167.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
TFSL
TFSL
Q4 25
$-25.4M
$58.7M
Q3 25
$-26.6M
$82.4M
Q2 25
$-23.3M
$26.8M
Q1 25
$-40.4M
$21.2M
Q4 24
$-18.8M
$45.5M
Q3 24
$-25.2M
$88.6M
Q2 24
$-29.1M
$96.7M
Q1 24
$-40.7M
$14.2M
Free Cash Flow
RYTM
RYTM
TFSL
TFSL
Q4 25
$57.1M
Q3 25
$71.0M
Q2 25
$25.0M
Q1 25
$14.3M
Q4 24
$44.9M
Q3 24
$85.5M
Q2 24
$95.9M
Q1 24
$13.4M
FCF Margin
RYTM
RYTM
TFSL
TFSL
Q4 25
68.2%
Q3 25
83.0%
Q2 25
30.5%
Q1 25
18.0%
Q4 24
60.0%
Q3 24
113.8%
Q2 24
127.0%
Q1 24
17.4%
Capex Intensity
RYTM
RYTM
TFSL
TFSL
Q4 25
2.0%
Q3 25
13.4%
Q2 25
2.1%
Q1 25
8.8%
Q4 24
0.9%
Q3 24
4.1%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
RYTM
RYTM
TFSL
TFSL
Q4 25
2.64×
Q3 25
3.17×
Q2 25
1.24×
Q1 25
1.01×
Q4 24
2.03×
Q3 24
4.86×
Q2 24
4.85×
Q1 24
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons